

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

03 FEB 14 AM 11:11

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name Pfizer, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 325 7th Street, N.W. Suite 1200 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name M. Kenneth Bowler	Telephone (202) 783-7070	E-mail (optional)	5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31354000

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <small>Income (nearest \$20,000)</small> Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,700,000.00</u> <small>Expenses (nearest \$20,000)</small> 14. REPORTING METHOD. Check box to indicate reporting method. See instructions for description <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6013 of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature


Date 2/14/2003

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues

HR 5263, Agriculture Appropriations, pharmaceutical counterfeiting, importation**S 2801, Agriculture Appropriations, pharmaceutical counterfeiting, importation****S 812, Greater Access to Affordable Pharmaceuticals Act of 2001, pharmaceutical counterfeiting, importation**

17. House(s) of Congress and Federal agencies contacted

 Check if None**House of Representatives****Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature

Date 2/14/2003

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

HR 5263, Agriculture Appropriations, pharmaceutical counterfeiting, importation**S 2778, Commerce, State, Justice Appropriations, intellectual property protection****S 2801, Agriculture Appropriations, pharmaceutical counterfeiting, importation****S 812, Greater Access to Affordable Pharmaceuticals Act or 2001, pharmaceutical counterfeiting, importation**

17. House(s) of Congress and Federal agencies contacted

 Check if None**House of Representatives****Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature

Date 2/14/2003

Printed Name and Title **M. Kenneth Bowler - Vice President, Federal Government Relations**

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

HR 1862 , The Greater Access to Affordable Pharmaceuticals Act of 2001, patents**HR 2887, The Better Pharmaceuticals for Children Act, pediatric pharmaceutical patents****S 2244, The Prescription Drug Price Parity for Americans Act , pharmaceutical counterfeiting****S 812, The Greater Access to Affordable Pharmaceuticals Act of 2001, patent issues**

17. House(s) of Congress and Federal agencies contacted

 Check if None**House of Representatives****Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature

Date 2/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues

S 2244, The Prescription Drug Price Parity for Americans Act, pharmaceutical counterfeiting, importation
S 2486, The Fair Advertising and Increased Research Act, advertising
Prescription and over the counter pharmaceuticals (no bills)

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature



Date 2/14/2003

Printed Name and Title M. Kenneth Bowler - Vice President, Federal Government Relations

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

HR 1624, Consumer Access to Prescription Drugs Improvement Act, access to pharmaceuticals

HR 2563, Bipartisan Patient Protection Act, liability issues

HR 2887, The Better Pharmaceuticals for Children Act, Pediatric pharmaceuticals

HR 3448, Prescription Drug User Fee Act Reauthorization of 2002, FDA user fees

HR 3804, Preservation of Antibiotics for Human Treatment Act, pharmaceutical issues

HR 4730, The Pediatric Drug Labeling Act, pediatric pharmaceuticals

HR 4954, Medicare Modernization and Prescription Drug Act of 2002, Medicare reform and prescription

S 10, Medicare Prescription Drug Coverage Act of 2001, Medicare reform

S 2394, The Pediatric Drug Labeling Act, pediatric pharmaceuticals

S 2536, State Medicaid Flexibility Act, medicaid and pharmaceutical coverage

S 357, Medicare Preservation and Improvement Act of 2001, Medicare reform

17. House(s) of Congress and Federal agencies contacted

 Check if None

Department of Health & Human Services

Executive Office of the President

Food & Drug Administration

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature

Date 2/14/2003

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

Item	Description	Data
16	Lobbying Issues	S 358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform and prescription drug benefit
16	Lobbying Issues	S 812, Greater Access to Affordable Pharmaceuticals Act of 2001, access to pharmaceuticals
16	Lobbying Issues	S 913, Consumer Access to Prescription Drugs Improvement Act, access to pharmaceuticals
16	Lobbying Issues	President Bush's Immediate Helping Hand Proposal (no bills) (drug benefit)

|

Registrant Name: Pfizer, Inc.Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

HR 4954, Medicare Modernization and Prescription Drug Act of 2002, Medicare reform
S 10, Medicare Prescription Drug Coverage Act of 2001, Prescription drug benefit
S 357, Medicare Preservation and Improvement Act of 2001, Medicare reform
S 358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform
S 812, Greater Access to Affordable Pharmaceuticals Act of 2001, Medicare reform
President Bush's Immediate Helping Hand Proposal (no bills) (drug benefit)

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

 Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
LaMarca, Louis A.	
McCarthy, Justin	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature


Date 2/14/2003

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

HR 3058, The Puppy Protection Act of 2001, animals in research

HR 3448, The Public Health Security and Bioterrorism Response Act of 2001, pharmaceutical supply and d

S 1478, The Puppy Protection Act of 2001, animals in research

S 1765, The Bioterrorism Preparedness Act, pharmaceutical supply and distribution

17. House(s) of Congress and Federal agencies contacted

Check if None

Department of Commerce

Department of Health & Human Services

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
LaMarca, Louis A.	
Mullen, Heather M.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature 

Date 2/14/2003

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

no bills, , International repatriation tax

S 2486, The Fair Advertising and Increased Research Act, tax deductions

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
Judge, Dolly	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature 

Date 2/14/2003

Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

- HR 3005, The Trade Promotion Authority Act of 2001, intellectual property protection**
- HR 3009, The Trade Act of 2002, intellectual property protection**
- S. 525, Andean Trade Preference Expansion Act of 2001, intellectual property protection**
- International intellectual property protection (no bills)**
- International pharmaceutical market access (no bills)**
- WTO accession and implementation issues (no bills)**

17. House(s) of Congress and Federal agencies contacted

Check if None

- Department of Commerce**
- Department of State**
- Executive Office of the President**
- House of Representatives**
- Office of U.S. Trade Representative**
- Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
Hardwick, Charles	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date 2/14/2003

Printed Name and Title **M. Kenneth Bowler - Vice President, Federal Government Relations**
